Transcode Net Working Capital from 2010 to 2026
| RNAZ Stock | USD 8.58 0.40 4.45% |
Net Working Capital | First Reported 2020-12-31 | Previous Quarter 6.7 M | Current Value 1.8 M | Quarterly Volatility 7.1 M |
Check Transcode Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Transcode Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 315.4 K, Interest Expense of 29.3 K or Selling General Administrative of 6.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Transcode financial statements analysis is a perfect complement when working with Transcode Therapeutics Valuation or Volatility modules.
Transcode | Net Working Capital | Build AI portfolio with Transcode Stock |
The evolution of Net Working Capital for Transcode Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Transcode Therapeutics compares to historical norms and industry peers.
Latest Transcode Therapeutics' Net Working Capital Growth Pattern
Below is the plot of the Net Working Capital of Transcode Therapeutics over the last few years. It is Transcode Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Transcode Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Working Capital | 10 Years Trend |
|
Net Working Capital |
| Timeline |
Transcode Net Working Capital Regression Statistics
| Arithmetic Mean | 2,391,768 | |
| Geometric Mean | 505,866 | |
| Coefficient Of Variation | 207.22 | |
| Mean Deviation | 3,046,438 | |
| Median | 141,529 | |
| Standard Deviation | 4,956,214 | |
| Sample Variance | 24.6T | |
| Range | 20.1M | |
| R-Value | 0.44 | |
| Mean Square Error | 21.1T | |
| R-Squared | 0.19 | |
| Significance | 0.08 | |
| Slope | 433,383 | |
| Total Sum of Squares | 393T |
Transcode Net Working Capital History
About Transcode Therapeutics Financial Statements
Transcode Therapeutics investors use historical fundamental indicators, such as Transcode Therapeutics' Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Transcode Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 5 M | 5.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.